Antibiotic Treatment—Much Better than Nothing

2019 ◽  
pp. 135-154
Author(s):  
Janet R. Gilsdorf
Keyword(s):  
Clinical Trials ◽  
Bacterial Meningitis ◽  
Antibiotic Treatment ◽  
Animal Experiments ◽  
Effective Management ◽  
Basic Principles ◽  
Duration Of Therapy ◽  
The Past ◽  
Drug Doses ◽  
Better Than

Over the past five decades, many animal experiments as well as clinical trials of antibiotics in humans treated for meningitis have defined the levels of antibiotics that are present in infected meninges and in the blood, thus informing the drug doses necessary to successfully treat the infection. In spite of the different kinds of bacteria that cause meningitis and the availability of various antibiotics to treat it, several basic principles of effective management for all common forms of bacterial meningitis have emerged from the decades of research. As a result of these studies, most children with meningitis in America receive appropriate antibiotic treatment (the correct antibiotic and the correct dose for the correct duration of therapy), and their outcomes are much, much better than the disastrous outcomes of earlier eras.

scholarly journals Calcium Antagonists, Cerebral Ischemia and Vasospasm

1984 ◽  
Vol 11 (2) ◽  
pp. 239-246 ◽  
Author(s):  
Bryce Weir
Keyword(s):  
Clinical Trials ◽  
Cerebral Ischemia ◽  
Calcium Ions ◽  
Calcium Antagonists ◽  
Animal Experiments ◽  
Arterial Occlusion ◽  
Transmembrane Transport ◽  
The Past ◽  
Systemic Arteries

ABSTRACT:The past fifteen years has seen the classification of diverse substances into a group known as calcium antagonists (CAs). They have a common ability to reduce the transmembrane transport of extracellular calcium ions (CAe2+). This flow of calcium into vascular smooth muscle is ultimately associated with the development of tension and vasoconstriction. Some CAs appear to have a predilection for cerebral as opposed to systemic arteries and so may function as specific cerebral arterial vasodilators. It has been proposed that they might be useful in certain types of cerebral ischemia such as that due to arterial occlusion or prolonged vasoconstriction. Animal experiments and initial clinical trials give grounds for cautious optimism that CAs may become as useful in neurology as they have recently become in cardiology.

Basic Studies of Various 99mTc-Labelled Renal Agents and Clinical Application of 99mTc-Malate

1977 ◽  
Vol 16 (01) ◽  
pp. 36-41 ◽  
Author(s):  
T. Machida ◽  
M. Miki ◽  
M. Ueda ◽  
A. Tanaka ◽  
I. Ikeda
Keyword(s):  
Excretion Rate ◽  
Animal Experiments ◽  
Imaging Agents ◽  
Half Time ◽  
Clinical Experiences ◽  
Labelling Efficiency ◽  
Urinary Excretion Rate ◽  
Renal Imaging ◽  
The Past ◽  
Basic Studies

SummaryVarious renal imaging agents that were reported in the past and a new agent, 99mTc-malate as well as 99mTc-cystein acetazolamide complex were prepared using electrolysis and electrochemical methods. These were studied for their labelling efficiency. After animal experiments with selected 99mTc-com- pounds, 99mTc-rnalate proved to be sufficient for renal imaging with adequate concentration. 99mTcmalate differs from other renal imaging agents in the utilization of endogeneous metabolic product.The first half time of 99mTc-malate in humans is 17 minutes, on the average, and the urinary excretion rate of 99mTc-malate is 36±6.05% in 1 hour after intravenous administration, 44 ± 3.41% in 2 hours and 50 + 5.62% in 3 hours.In our 40 clinical experiences of 99m-Tc-rnalate, most cases demonstrated quite clear renal images in the serial scintiphotos except cases whose serum creatinines were over 4.5 mg/dl.

Implementasi Algoritma Hamming Distance dan Brute Force dalam Mendeteksi Kemiripan Source Code Bahasa Pemrograman C

2017 ◽  
Vol 8 (2) ◽  
Author(s):  
Andreas Budiman ◽  
Dennis Gunawan ◽  
Seng Hansun
Keyword(s):  
College Presidents ◽  
Hamming Distance ◽  
Source Code ◽  
Structural Type ◽  
Brute Force ◽  
Important Thing ◽  
The Past ◽  
Index Terms ◽  
Better Than

Plagiarism is a behavior that causes violence of copyrights. Survey shows 55% of college presidents say that plagiarism in students’ papers has increased over the past 10 years. Therefore, an application for detecting plagiarism is needed, especially for teachers. This plagiarism checker application is made by using Visual C# 2010. The plagiarism checker uses hamming distance algorithm for matching line code of the source code. This algorithm works by matching the same length string of the code programs. Thus, it needs brute will be matched with hamming distance. Another important thing for detecting plagiarism is the preprocessing, which is used to help the algorithm for detecting plagiarized source code. This paper shows that the application works good in detecting plagiarism, the hamming distance algorithm and brute force algorithm works better than levenstein distance algorithm for detecting structural type of plagiarism and this thesis also shows that the preprocessing could help the application to increase its percentage and its accuracy. Index Terms—Brute Force, Hamming Distance, Plagiarisme, Preprocessing.

Ways of Being and Time

2017 ◽  
Author(s):  
Kris McDaniel
Keyword(s):  
Being And Time ◽  
Present Moment ◽  
Ontological Pluralism ◽  
The Past ◽  
Mode Of Being ◽  
Ways Of Being ◽  
Better Than

This chapter develops a version of ontological pluralism that respects two common intuitions about time: that the present moment is metaphysically distinguished but not in such a way that the past is unreal. The version of ontological pluralism developed—presentist existential pluralism (PEP)—embraces two modes of being, the mode of being that present objects enjoy and the mode of being that past objects enjoy. The author argues that this view fares at least as well, and probably better, than other views in which the present is metaphysically distinguished. The chapter also introduces another form of ontological superiority called “levels of being.”

scholarly journals ANCA Status or Clinical Phenotype — What Counts More?

2021 ◽  
Vol 23 (6) ◽  
Author(s):  
Martin Windpessl ◽  
Erica L. Bettac ◽  
Philipp Gauckler ◽  
Jae Il Shin ◽  
Duvuru Geetha ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Granulomatosis With Polyangiitis ◽  
Clinical Phenotype ◽  
Antineutrophil Cytoplasmic Antibody ◽  
Cardiovascular Death ◽  
Genetic Associations ◽  
Ongoing Debate ◽  
The Past ◽  
Anca Associated Vasculitis

Abstract Purpose of Review There is ongoing debate concerning the classification of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. That is, whether classification should be based on the serotype (proteinase 3 (PR3)- or myeloperoxidase (MPO)-ANCA) or on the clinical phenotype (granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)). To add clarity, this review focused on integration of the most recent literature. Recent Findings Large clinical trials have provided evidence that a serology-based risk assessment for relapses is more predictive than distinction based on the phenotype. Research conducted in the past decade indicated that a serology-based approach more closely resembles the genetic associations, the clinical presentation (i.e., lung involvement), biomarker biology, treatment response, and is also predicting comorbidities (such as cardiovascular death). Summary Our review highlights that a serology-based approach could replace a phenotype-based approach to classify ANCA-associated vasculitides. In future, clinical trials and observational studies will presumably focus on this distinction and, as such, translate into a “personalized medicine.”

scholarly journals Mesenchymal stem cells and oncolytic viruses: joining forces against cancer

2021 ◽  
Vol 9 (2) ◽  
pp. e001684
Author(s):  
Rafael Moreno
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Immune System ◽  
Oncolytic Viruses ◽  
Immunogenic Cell Death ◽  
The Past ◽  
Physical Barriers ◽  
Immunogenic Properties ◽  
New Strategies

The development of oncolytic viruses (OVs) has increased significantly in the past 20 years, with many candidates entering clinical trials and three of them receiving approval for some indications. Recently, OVs have also gathered interest as candidates to use in combination with immunotherapies for cancer due to their immunogenic properties, which include immunogenic cell death and the possibility to carry therapeutic transgenes in their genomes. OVs transform non-immunogenic ‘cold’ tumors into inflamed immunogenic ‘hot’ tumors, where immunotherapies show the highest efficacy. However, in monotherapy or in combination with immunotherapy, OVs face numerous challenges that limit their successful application, in particular upon systemic administration, such as liver sequestration, neutralizing interactions in blood, physical barriers to infection, and fast clearance by the immune system. In this regard, the use of mesenchymal stem cells (MSCs) as cells carrier for OV delivery addresses many of these obstacles acting as virus carriers and factories, expressing additional transgenes, and modulating the immune system. Here, I review the current progress of OVs-loaded MSCs in cancer, focusing on their interaction with the immune system, and discuss new strategies to improve their therapeutic efficacy.

Taking Peritoneal Dialysis beyond the Year 2000

1999 ◽  
Vol 19 (3_suppl) ◽  
pp. 35-42 ◽  
Author(s):  
Ram Gokal
Keyword(s):  
Peritoneal Dialysis ◽  
Peritoneal Membrane ◽  
Membrane Function ◽  
Fluid Removal ◽  
The Past ◽  
First Choice ◽  
Year 2000 ◽  
Economic Considerations ◽  
Appropriate Prescription ◽  
Better Than

Over the past 25 years, peritoneal dialysis (PD) has steadily improved so that now its outcomes, in the form of patient survival, are equivalent to, and at times better than, those for hemodialysis. We now have a better understanding of the pathophysiology of peritoneal membrane function and damage and the importance of appropriate prescription to meet agreed-upon targets of solute and fluid removal. In the next millennium, greater emphasis will be put on prescription setting and subsequent monitoring. This will entail an increase in automated PD, especially for lifestyle reasons as well as for patients with a hyperpermeable peritoneal membrane. To improve outcomes, dialysis should be started earlier than is currently the case. It is easy to do this with PD, where an incremental approach is made easier by the introduction of icodextrin for long-dwell PD. In the future, solutions will be tailored to be more biocompatible and to provide improved nutrition and better cardiovascular outcomes. Finally, economic considerations favor PD, which is cheaper than in-centre hemodialysis. Thus, for many, PD has become a first-choice therapy, and with further improvements this trend will continue.

scholarly journals How I treat pediatric venous thromboembolism

Blood ◽  
2017 ◽  
Vol 130 (12) ◽  
pp. 1402-1408 ◽  
Author(s):  
Guy Young
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Large Scale ◽  
Central Venous Catheters ◽  
Rare Disorder ◽  
Central Venous ◽  
Management Decisions ◽  
Logical Approach ◽  
The Past ◽  
Medical Disorders

Abstract The incidence of pediatric venous thromboembolism (VTE) has been increasing significantly over the past decade in part as a result of increased recognition of this serious disorder but more so because of the increased use of central venous catheters and other technological advancements involved in the care of ill children. Management of pediatric VTE is a complex undertaking, considering that the vast majority of children who develop this complication have serious underlying medical disorders. Although the incidence is rising, in comparison with adults, this remains a relatively rare disorder, and as such, large-scale clinical trials have not been completed, rendering management decisions to be based on extrapolation from adult data and the experience of the treating physician. Clearly, both are fraught with problems. Thus, day-to-day management remains more art than science until such time that the results from clinical trials (many of which are under way) become available. This edition of “How I Treat” describes the author’s experience in managing 3 common scenarios that one may encounter in pediatric thrombosis and suggests a logical approach to such situations. Furthermore, the author provides 3 algorithms to help guide management decisions.

Sign in / Sign up

Export Citation Format

Share Document